Piroxicam in osteoarthritis: a controlled long-term study

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Medicine

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease.
• Effective pain management and improved joint function are key treatment goals for OA patients.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for OA symptom management.

Purpose of the Study:

• To compare the efficacy and safety of two piroxicam dosages (20 mg and 40 mg) against aspirin in patients with osteoarthritis.
• To evaluate physician-assessed improvement and ease of movement in OA patients treated with piroxicam versus aspirin.

Main Methods:

• A six-month, double-blind, parallel-design clinical trial.
• Involved 29 patients diagnosed with osteoarthritis.
• Compared piroxicam (20 mg and 40 mg) with 12 tablets of aspirin.

Main Results:

• Both piroxicam dosages showed superior efficacy compared to aspirin, based on physician assessments of improvement and joint mobility.
• The safety profiles of piroxicam 20 mg and aspirin were comparable.
• Gastrointestinal side effects were the most frequently reported adverse events in the study.

Conclusions:

• Piroxicam is an effective treatment option for osteoarthritis, offering better symptom relief and improved joint function compared to aspirin.
• Piroxicam demonstrates a comparable safety profile to aspirin, with gastrointestinal issues being the primary concern.
• Patients treated with piroxicam are enrolled in an ongoing five-year study to further assess long-term efficacy and safety.